Recall: D-0728-2026

Class II - Potentially Harmful

Class IIClassification

2026-07-16Initiated

OngoingStatus

Fresenius Kabi USA, LLCFirm

Product

Xylocaine (lidocaine HCl Injection, USP), 1%, 200 mg per 20 mL (10 mg per mL), 25 Multiple-Dose Vials, 20 mL, Rx only, Sterile, Fresenius Kabi, Lake Zurich, IL 60047 NDC Tray: 63323-485-27; NDC Vial: 63323-485-01

Reason

Presence of Particulate Matter: Hair was found in products

Distribution

Nationwide within in the USA

Source: FDA drug enforcement report via openFDA (Voluntary: Firm initiated). If you take this product, talk to your pharmacist or doctor before stopping it.